Department of Systems Biology & the Gehr Family Center for Leukemia Research, the Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Department of Systems Biology & the Gehr Family Center for Leukemia Research, the Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou 510005, China.
Cancer Cell. 2020 Mar 16;37(3):270-288. doi: 10.1016/j.ccell.2020.02.004.
N-Methyladenosine (mA) RNA modification has emerged in recent years as a new layer of regulatory mechanism controlling gene expression in eukaryotes. As a reversible epigenetic modification found not only in messenger RNAs but also in non-coding RNAs, mA affects the fate of the modified RNA molecules and plays important roles in almost all vital bioprocesses, including cancer development. Here we review the up-to-date knowledge of the pathological roles and underlying molecular mechanism of mA modifications (in both coding and non-coding RNAs) in cancer pathogenesis and drug response/resistance, and discuss the therapeutic potential of targeting mA regulators for cancer therapy.
N6-甲基腺苷（m6A）RNA 修饰作为一种新的调控机制，近年来在真核生物中控制基因表达方面备受关注。m6A 是一种可逆的表观遗传修饰，不仅存在于信使 RNA 中，也存在于非编码 RNA 中，它影响修饰 RNA 分子的命运，并在几乎所有重要的生物过程中发挥重要作用，包括癌症的发展。本文综述了 m6A 修饰（在编码和非编码 RNA 中）在癌症发病机制和药物反应/耐药性中的病理作用和潜在分子机制的最新知识，并讨论了针对 m6A 调节剂治疗癌症的治疗潜力。
